arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

AYTU BIOPHARMA, INC

AYTU
$2.33 ▲ +0.03 (+1.30%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
85 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

AYTU BIOPHARMA, INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $24.5M
Dividend Yield
Revenue Growth -32.7%
Op. Margin -32.7%
ROIC -9.1%
FCF / Share $-0.40
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity 0.27
info Valuation on last close. End-of-day price, Aug 7, 2026.

85-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.41M
↓ -32.7%
Net Income Profit after all expenses
$1.97M
↑ +33.3%
Operating Margin Operating profit as % of sales
-32.7%
↓ -152.1% 14th
FCF / Share Free cash flow per share
$-0.40
↓ -209.2%
Long-Term Debt Long-term obligations
$9.55M
↓ -4.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
12
Financial Health
43
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 21 years · 85 quarters